CRChristopher P. Randall

Christopher P. Randall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christopher P. Randall has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nature of bacitracin resistance in Staphylococcus aureus

    by Merianne Mohamad, Mollie M. Hurst, Elham Elkrewi, Christopher P. Randall, Alex J. O’nEill

    Bacitracin is employed for topical treatment of staphylococcal infection, though information is lacking regarding the nature of resistance to this antibiotic in the staphylococci. Here we examined bacitracin resistance in a large collection ( n = 1,470) of multidrug-resistant isolates of Staphylococcus aureus . Susceptibility testing of the entire collection revealed a broad range of bacitracin minimum inhibitory concentrations (MICs) (from 32 to >4,096 µg/mL) and allowed us to define a tentative epidemiological cut-off value (TECOFF) (apparent upper end of the wild-type distribution in terms of bacitracin susceptibility) of 256 µg/mL. On the basis of this TECOFF, 101 strains (6.8% of the total) for which bacitracin had an MIC of ≥512 µg/mL were considered resistant. Bacitracin resistance was found across multiple sequence types (STs), though over half the resistant strains belonged to the ST8:USA300 lineage. In nearly all bacitracin-resistant strains (99 of 101), whole genome sequence analysis identified operons similar to the bcrABD operon that confers bacitracin resistance in Enterococcus faecalis ; 3 strains carried an operon [ bcrAB (ISL3) D ] closely related to the latter (~90% identity in the encoded resistance proteins), while 96 strains harbored a more distantly related operon (bcrEFH . Molecular cloning experiments confirmed the ability of both bcr operons to confer bacitracin resistance in S. aureus . Both bcrAB (ISL3) D and bcrEFH reside on IS 6 -flanked pseudo-compound transposons on multidrug resistance plasmids, highlighting their potential to spread and become more widely disseminated among staphylococci.


  • Open Access

    Transient Silencing of Antibiotic Resistance by Mutation Represents a Significant Potential Source of Unanticipated Therapeutic Failure

    by Louise Kime, Christopher P Randall, Frank I Banda, Francesc Coll, John Wright, Joseph Richardson, Joanna Empel, Julian Parkhill, Alex J O'Neill

    Sporadic literature reports describe isolates of pathogenic bacteria that harbor an antibiotic resistance determinant but remain susceptible to the corresponding antibiotic as a consequence of a genetic defect. Such strains represent a source from which antibiotic resistance may reemerge to cause treatment failure in patients. Here, we report a systematic investigation into the prevalence and nature of this phenomenon, which we term silencing of antibiotic resistance by mutation (SARM). Instances of SARM were detected among 1,470 Staphylococcus aureus isolates through side-by-side comparison of antibiotic resistance genotype (as determined by whole-genome sequencing) versus phenotype (as assessed through susceptibility testing). Of the isolates analyzed, 152 (10.3%) harbored a silenced resistance gene, including 46 (3.1%) that exhibited SARM to currently deployed antistaphylococcal drugs. SARM resulted from diverse mutational events but most commonly through frameshift mutation of resistance determinants as a result of point deletion in poly(A) tracts. The majority (∼90%) of SARM strains reverted to antibiotic resistance at frequencies of ≥10−9; thus, while appearing antibiotic sensitive in the clinical microbiology laboratory, most S. aureus isolates exhibiting SARM will revert to antibiotic resistance at frequencies achievable in patients. In view of its prevalence in a major pathogen, SARM represents a major potential threat to the therapeutic efficacy of antibiotics. IMPORTANCE Antibiotic resistance hinders the treatment of bacterial infection. To guide effective therapy, clinical microbiology laboratories routinely perform susceptibility testing to determine the antibiotic sensitivity of an infecting pathogen. This approach relies on the assumption that it can reliably distinguish bacteria capable of expressing antibiotic resistance in patients, an idea challenged by the present study. We report that the important human pathogen Staphylococcus aureus frequently carries antibiotic resistance genes that have become inactivated (“silenced”) by mutation, leading strains to appear antibiotic sensitive. However, resistance can rapidly reemerge in most such cases, at frequencies readily achievable in infected patients. Silent antibiotic resistance is therefore prevalent, transient, and evades routine detection, rendering it a major potential threat to antibacterial chemotherapy.


  • Open Access

    Acquired Nisin Resistance in Staphylococcus aureus Involves Constitutive Activation of an Intrinsic Peptide Antibiotic Detoxification Module

    by Christopher P. Randall, Arya Gupta, Bret Utley-Drew, Siu Yi Lee, Genevieve Morrison-Williams, Alex J. O’neill

    NIS and related bacteriocins are of interest as candidates for the treatment of human infections caused by Gram-positive pathogens such as Staphylococcus aureus . An important liability of NIS in this regard is the ease with which S. aureus acquires resistance. Here we establish that this organism naturally possesses the cellular machinery to detoxify NIS but that the ABC transporter responsible (VraDE) is not ordinarily produced to a degree sufficient to yield substantial resistance. Acquired NIS resistance mutations prompt activation of the regulatory circuit controlling expression of vraDE , thereby unmasking an intrinsic resistance determinant. Our results provide new insights into the complex mechanism by which expression of vraDE is regulated and suggest that a potential route to overcoming the resistance liability of NIS could involve chemical modification of the molecule to prevent its recognition by the VraDE transporter.


  • N-Leucinyl Benzenesulfonamides as Structurally Simplified Leucyl-tRNA Synthetase Inhibitors

    by Michael H. Charlton, Rihards Aleksis, Adélaïde Saint-Leger, Arya Gupta, Einars Loza, Lluís Ribas de Pouplana, Ilze Kaula, Daina Gustina, Marina Madre, Daina Lola, et al.

    N-Leucinyl benzenesulfonamides have been discovered as a novel class of potent inhibitors of E. coli leucyl-tRNA synthetase. The binding of inhibitors to the enzyme was measured by using ITC. This provided information on enthalpy and entropy contributions to binding, which, together with docking studies, were used for SAR analysis. Enzymatic assays revealed that N-leucinyl benzene-sulfonamides display remarkable selectivity for E. coli leucyl-tRNA synthetase compared to S. aureus and human orthologs. The simplest analog of the series _ N-leucinyl benzenesulfonamide (R = H) showed the highest affinity against E. coli leucyl-tRNA syn-thetase and also exhibited antibacterial activity against gram-negative pathogens (the best MIC = 8 ug/mL, E. coli ATCC 25922) which renders it as a promising template for antibacterial drug discovery.


  • Open Access

    Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin

    by Nada M. Nass, Sannia Farooque, Charlotte Hind, Matthew E. Wand, Christopher P. Randall, J. Mark Sutton, Ryan F. Seipke, Christopher M. Rayner, Alex J. O’neill

    Of the thousands of natural product antibiotics discovered to date, only a handful have been developed for the treatment of bacterial infection. The clinically unexploited majority likely include compounds with untapped potential as antibacterial drugs, and in view of the ever-growing unmet medical need for such agents, warrant systematic re-evaluation. Here we revisit the actinorhodins, a class that was first reported 70 years ago, but which remains poorly characterized. We show that γ-actinorhodin possesses many of the requisite properties of an antibacterial drug, displaying potent and selective bactericidal activity against key Gram-positive pathogens (including Staphylococcus aureus and enterococci), a mode of action distinct from that of other agents in clinical use, an extremely low potential for the development of resistance, and a degree of in vivo efficacy in an invertebrate model of infection. Our findings underscore the utility of revisiting unexploited antibiotics as a source of novel antibacterial drug candidates.


  • Impact of Exposure of Methicillin-Resistant Staphylococcus aureus to Polyhexanide In Vitro and In Vivo

    by A. Renzoni, E. Von Dach, C. Landelle, S. M. Diene, C. Manzano, R. Gonzales, W. Abdelhady, C. P. Randall, E. J. Bonetti, D. Baud, et al.

    Methicillin-resistant Staphylococcus aureus (MRSA) resistant to decolonization agents such as mupirocin and chlorhexidine increases the need for development of alternative decolonization molecules. The absence of reported severe adverse reactions and bacterial resistance to polyhexanide makes it an excellent choice as a topical antiseptic. In the present study, we evaluated the in vitro and in vivo capacity to generate strains with reduced polyhexanide susceptibility and cross-resistance with chlorhexidine and/or antibiotics currently used in clinic. Here we report the in vitro emergence of reduced susceptibility to polyhexanide by prolonged stepwise exposure to low concentrations in broth culture. Reduced susceptibility to polyhexanide was associated with genomic changes in the mprF and purR genes and with concomitant decreased susceptibility to daptomycin and other cell wall-active antibiotics. However, the in vitro emergence of reduced susceptibility to polyhexanide did not result in cross-resistance to chlorhexidine. During in vivo polyhexanide clinical decolonization treatment, neither reduced polyhexanide susceptibility nor chlorhexidine cross-resistance was observed. Together, these observations suggest that polyhexanide could be used safely for decolonization of carriers of chlorhexidine-resistant S. aureus strains; they also highlight the need for careful use of polyhexanide at low antiseptic concentrations.


  • Open Access

    Cryptic silver resistance is prevalent and readily activated in certain Gram-negative pathogens

    by Elham Elkrewi, Christopher P Randall, Nicola Ooi, Jennifer L Cottell, Alex J O’neill

    To assess the prevalence of cryptic silver (Ag+) resistance amongst clinical isolates of Gram-negative bacteria, and to examine how overt Ag+ resistance becomes activated in such strains. Established methods were used to determine the susceptibility of 444 recent clinical isolates to Ag+, and to evaluate the potential for overt Ag+ resistance to emerge in susceptible isolates by spontaneous mutation. The genetic basis for Ag+ resistance was investigated using PCR amplification and DNA sequencing. None of the isolates tested displayed overt Ag+ resistance. However, upon silver challenge, high-level Ag+ resistance (silver nitrate MIC >128 mg/L) was selected at high frequency (10−7 to 10−8) in 76% of isolates of Enterobacter spp., ∼58% of isolates of Klebsiella spp. and ∼0.7% of isolates of Escherichia coli. All strains in which Ag+ resistance could be selected harboured the sil operon, with resistance apparently resulting from activation of this system as a consequence of single missense mutations in silS. By contrast, Ag+ resistance was not selected in isolates lacking sil, which included all tested representatives of Pseudomonas aeruginosa, Acinetobacter spp., Citrobacter spp. and Proteus spp. Whilst overt Ag+ resistance in Gram-negative pathogens is uncommon, cryptic Ag+ resistance pertaining to the sil operon is prevalent and readily activated in particular genera (Enterobacter and Klebsiella).


  • Targeting Multiple Aminoacyl-tRNA Synthetases Overcomes the Resistance Liabilities Associated with Antibacterial Inhibitors Acting on a Single Such Enzyme

    by Christopher P. Randall, Dace Rasina, Aigars Jirgensons, Alex J. O'NEill

    Bacterial aminoacyl-tRNA synthetases (aaRSs) represent promising antibacterial drug targets. Unfortunately, the aaRS inhibitors that have to date reached clinical trials are subject to rapid resistance development through mutation, a phenomenon that limits their potential clinical utility. Here, we confirm the intuitively correct idea that simultaneous targeting of two different aaRS enzymes prevents the emergence of spontaneous bacterial resistance at high frequency, a finding that supports the development of multitargeted anti-aaRS therapies.


  • Open Access

    A Polymorphism in leuS Confers Reduced Susceptibility to GSK2251052 in a Clinical Isolate of Staphylococcus aureus

    by Arya Gupta, Carmine Monteferrante, Dace Rasina, Gundars Leitis, Christopher P. Randall, Jennifer H. Tomlinson, Aigars Jirgensons, Wil H. F. Goessens, John P. Hays, Alex J. O'Neill

    GSK2251052 is a broad-spectrum antibacterial inhibitor of leucyl tRNA-synthetase (LeuRS) that has been evaluated in phase II clinical trials. Here, we report the identification of a clinical isolate of Staphylococcus aureus that exhibits reduced susceptibility to GSK2251052 without prior exposure to the compound and demonstrate that this phenotype is attributable to a single amino acid polymorphism (P 329 ) within the editing domain of LeuRS.


  • Open Access

    Silver resistance in Gram-negative bacteria: a dissection of endogenous and exogenous mechanisms

    by Christopher P. Randall, Arya Gupta, Nicole Jackson, David Busse, Alex J. O'Neill

    To gain a more detailed understanding of endogenous (mutational) and exogenous (horizontally acquired) resistance to silver in Gram-negative pathogens, with an emphasis on clarifying the genetic bases for resistance. A suite of microbiological and molecular genetic techniques was employed to select and characterize endogenous and exogenous silver resistance in several Gram-negative species. In Escherichia coli, endogenous resistance arose after 6 days of exposure to silver, a consequence of two point mutations that were both necessary and sufficient for the phenotype. These mutations, in ompR and cusS, respectively conferred loss of the OmpC/F porins and derepression of the CusCFBA efflux transporter, both phenotypic changes previously linked to reduced intracellular accumulation of silver. Exogenous resistance involved derepression of the SilCFBA efflux transporter as a consequence of mutation in silS, but was additionally contingent on expression of the periplasmic silver-sequestration protein SilE. Silver resistance could be selected at high frequency (>10−9) from Enterobacteriaceae lacking OmpC/F porins or harbouring the sil operon and both endogenous and exogenous resistance were associated with modest fitness costs in vitro. Both endogenous and exogenous silver resistance are dependent on the derepressed expression of closely related efflux transporters and are therefore mechanistically similar phenotypes. The ease with which silver resistance can become selected in some bacterial pathogens in vitro suggests that there would be benefit in improved surveillance for silver-resistant isolates in the clinic, along with greater control over use of silver-containing products, in order to best preserve the clinical utility of silver.